Compass Therapeutics, Inc.CMPXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank71
3Y CAGR-12.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-12.2%/yr
Annual compound
Percentile
P71
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 32.18% |
| 2024 | 11.08% |
| 2023 | 27.08% |
| 2022 | 47.50% |
| 2021 | 36.45% |
| 2020 | -33.61% |
| 2019 | -17.15% |
| 2018 | 0.00% |